W
Werner Kissling
Researcher at Technische Universität München
Publications - 200
Citations - 17324
Werner Kissling is an academic researcher from Technische Universität München. The author has contributed to research in topics: Antipsychotic & Amisulpride. The author has an hindex of 55, co-authored 200 publications receiving 15965 citations. Previous affiliations of Werner Kissling include Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht,Andrea Cipriani,Andrea Cipriani,Loukia M. Spineli,Dimitris Mavridis,Deniz Örey,Franziska Richter,Myrto Samara,Corrado Barbui,Rolf R. Engel,John R. Geddes,Werner Kissling,Marko Paul Stapf,Bettina Lässig,Georgia Salanti,John M. Davis +15 more
TL;DR: A Bayesian-framework, multiple-treatments meta-analysis of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia found all drugs were significantly more effective than placebo.
Journal ArticleDOI
What does the PANSS mean
Stefan Leucht,Stefan Leucht,John M. Kane,Werner Kissling,Johannes Hamann,Eva Etschel,Rolf R. Engel +6 more
TL;DR: The results provide a better framework for understanding the clinical meaning of the PANSS total score in drug trials of schizophrenia patients with acute exacerbations and may ideally use at least a 50% reduction from baseline cut-off to define response rather than lower thresholds.
Journal ArticleDOI
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
TL;DR: All of the 4 new drugs are more effective than placebo, but the magnitude of the effect is only moderate, and all new antipsychotics are associated with less frequent use of antiparkinson medication than haloperidol.
Journal ArticleDOI
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
Stefan Leucht,Magdolna Tardy,Katja Komossa,Stephan Heres,Werner Kissling,Georgia Salanti,John M. Davis +6 more
TL;DR: Maintenance treatment with antipsychotic drugs benefits patients with schizophrenia and the advantages of these drugs must be weighed against their side-effects.
Journal ArticleDOI
Clinical implications of Brief Psychiatric Rating Scale scores.
TL;DR: The results provide a clearer understanding of how to interpret BPRS total and percentage reduction scores in clinical trials with patients acutely ill with schizophrenia who are experiencing positive symptoms.